How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation
| Autor: | Bing-Sheng Li, Qingchun Zeng, Wei-Hong Zhao, Rui-lin Chen, Bin-Tao Huang |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Cyclophosphamide Chronic lymphocytic leukemia Gastroenterology Disease-Free Survival Antibodies Monoclonal Murine-Derived Risk Factors Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans In patient Prospective Studies Adverse effect Aged Aged 80 and over Hematology business.industry General Medicine medicine.disease Leukemia Lymphocytic Chronic B-Cell Fludarabine Treatment Outcome Oncology Immunology Cohort Rituximab Female business Vidarabine medicine.drug Follow-Up Studies |
| Zdroj: | Medical oncology (Northwood, London, England). 31(8) |
| ISSN: | 1559-131X |
| Popis: | The open-label, prospective, observational study aimed to evaluate whether the addition of maintenance rituximab (MR) improved progression-free survival (PFS) and overall survival (OS), after fludarabine, cyclophosphamide, and rituximab (FCR) for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia (CLL). Enrolled 201 patients (ages 65–84 years) who received FCR and gained an overall response. One hundred and four of 201 patients were in the observation (OBS) arm while 97/201 patients continued to receive MR therapy. After FCR, no more benefits were provided by MR versus OBS in cytogenetic better intermediate-risk cohort. PFS at 10 years reached 68.6 versus 58.1 % (P > 0.05). Ten-year OS was 81.8 versus 74.6 % (P > 0.05). However, the improvement of PFS and OS were as dramatic as the improvements of being MR treating versus OBS mainly in the poor-risk cohort. PFS at 10 years reached 57.1 versus 22.7 % (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink